Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART

HIV Clinical Trials

Volumn 2, Issue 1, 2001, Pages 38-45

  Duran, S ^a   Spire, B ^a   Raffi, F ^a   Walter, V ^a   Bouhour, D ^a   Journot, V ^a   Cailleton, V ^a   Leport, C ^a   Moatti, J P ^a  

^a INSERM   (France)

Author keywords

Adherens; HAART; Self related symptoms

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SELF ADMINISTRATION; FATIGUE; FEMALE; FEVER; HEADACHE; HEARTBURN; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MOUTH LESION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROLITHIASIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RISK; SELF REPORT; SIDE EFFECT; SOCIAL SUPPORT; STOMACH PAIN; SYMPTOM; TASTE; TREATMENT OUTCOME; VOMITING;

EID: 0035119211     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/R8M7-EQ0M-CNPW-39FC     Document Type: Article

References (42)

1. Public health implications of antiretroviral therapy arid HIV drug resistance
2. Potential factors affecting adherence with HIV therapy
3. Rethinking non-adherence: Historical perspectives on triple-drug therapy for HIV disease
4. Adherence to HIV combination therapy
5. Compliance/adherence and care management in HIV disease
6. Antiretroviral therapy for HIV infection (n 1997. Updated recommendations of the International AIDS Society-USA panel
7. HIV-1 protease inhibitors. A review for clinicians
8. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
9. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
10. Adherence to combination antiretroviral therapies in HIV patients of low health literacy
11. Adherence to complex antlretroviral therapies by HIV-positive drug abusers
12. Sociodemographic and psychological variables influencing adherence to antiretrovial therapy
13. Protease inhibitors in the homeless
14. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment
15. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants
16. HIV-protease inhibitors
17. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued?
18. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data
19. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial
20. A cohort study of drug users' compliance with zidovudine treatment
21. Determinants of subject compliance within an experimental anti-HIV drug protocol
22. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease
23. Clinical implications of alcoholism in patients with HIV/AIDS
24. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
25. The influence of values and culture in responses to suffering
26. Zidovudine adherence among individuals with HIV infection
27. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
28. Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: An issue for quality of care
29. The quality of life of patients with newly diagnosed M1 prostate cancer: Experience with EORTC clinical trial 30853
30. Physicians' recognition of the symptoms experienced by HIV patients: How reliable?
31. Factors affecting adherence to antiretroviral therapy
32. Self-reported adherence to HAART and correlation with HIV RNA: Initial results with the patient medication adherence questionnaire
33. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens
34. Compliance issues in quality of life assessment: Experiences of two cancer research campaign sponsored groups
35. Patient "non-compliance" and "missing data" in quality of life research: Where does the problem lie?
36. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor
37. Adherence to very active antiretroviral treatment: Impact of individualized assessment
38. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications
39. Adherence communication: A qualitative analysis of physician-patient dialogue
40. La version frana̧ise de l'échelle CES-D. Description and translation of the autoevaluation scale [in French]